The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen announced it will present its novel modifier gene therapy platform at several key scientific conferences in 2026, including the EIS 2026, the 26th EURETINA Congress, and the AAO Annual Meeting.
This move highlights Ocugen's continued focus on innovative genetic therapies within the ophthalmology field as it seeks to advance its research at major industry gatherings.
View post on X Loading...
Earlier this year, Ocugen launched an Expanded Access Program in the Bahamas to provide commercial access to its OCU400 therapy for retinitis pigmentosa, according to company disclosures. The firm also recently welcomed Pennsylvania lawmakers to its facility to discuss its biotech pipeline and state research initiatives, as detailed in a previous report. These efforts reflect Ocugen's ongoing engagement in genetic therapy development and collaboration with regulatory stakeholders.